• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>World Journal of Vaccines >Therapeutic MUC1-Based Cancer Vaccine Expressed in Flagella-Efficacy in an Aggressive Model of Breast Cancer
【24h】

Therapeutic MUC1-Based Cancer Vaccine Expressed in Flagella-Efficacy in an Aggressive Model of Breast Cancer

机译：在侵略性乳腺癌模型中鞭毛功效中表达的基于治疗性MUC1的癌症疫苗。

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

MUC1, a tumor-associated antigen overexpressed in many carcinomas, represents a candidate of choice for cancer immunotherapy. Flagella-based MUC1 vaccines were tested in therapeutic setting in two aggressive breast cancer models, comprising the implantation of the 4T1-MUC1 cell line in either Balb/c, or Human MUC1 transgenic mice in which spontaneous metastases occurs. Recombinant flagella carrying only 7 amino acid of MUC1 elicited therapeutic activity, affecting both the growth of established growing tumors and the number of metastases. Higher therapeutic activity was achieved with an additional recombinant flagella designed with the SYFPEITHI algorithm. The vaccines triggered a Th1 response against MUC1 with no evident autoimmune response towards healthy MUC1-expressing tissues. Recombinant flagella carrying a 25-residue fragment of MUC1, induced the most effective response, as evidenced by a significant reduction of both the size and growth rate of the tumor as well as by the lower number of metastases, and expanding life span of vaccinated mice.
机译：MUC1是一种在许多癌症中过表达的肿瘤相关抗原，代表了癌症免疫治疗的候选选择。在两个侵略性乳腺癌模型的治疗环境中测试了基于鞭毛的MUC1疫苗，包括在发生自发转移的Balb / c或人MUC1转基因小鼠中植入4T1-MUC1细胞系。仅携带MUC1的7个氨基酸的重组鞭毛引发了治疗活性，既影响了已建立的正在生长的肿瘤的生长又影响了转移的数量。用SYFPEITHI算法设计的其他重组鞭毛可实现更高的治疗活性。疫苗触发了针对MUC1的Th1反应，而对健康的表达MUC1的组织没有明显的自身免疫反应。带有25个残基MUC1片段的重组鞭毛诱导了最有效的反应，肿瘤大小和生长速度的显着降低以及转移的数量减少以及接种小鼠的寿命延长证明了这一点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号